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ABSTRACT
Regulatory T-cells (Treg) play an essential role in the
negative regulation of immune answers by develop-
ing an attenuated cytokine response that allows
suppressing proliferation and effector function of
T-cells (CD4
+ Th). The transcription factor FoxP3 is
responsible for the regulation of many genes invol-
ved in the Treg gene signature. Its ablation leads to
severe immune deficiencies in human and mice.
Recent developments in sequencing technologies
have revolutionized the possibilities to gain insights
into transcription factor binding by ChiP-seq and
into transcriptome analysis by mRNA-seq. We
combine FoxP3 ChiP-seq and mRNA-seq in order
to understand the transcriptional differences
between primary human CD4
+ T helper and regula-
tory T-cells, as well as to study the role of FoxP3 in
generating those differences. We show, that mRNA-
seq allows analyzing the transcriptomal landscape
of T-cells including the expression of specific splice
variants at much greater depth than previous
approaches, whereas 50% of transcriptional regula-
tion events have not been described before by using
diverse array technologies. We discovered splicing
patterns like the expression of a kinase-dead iso-
form of IRAK1 upon T-cell activation. The immuno-
proteasome is up-regulated in both Treg and CD4
+
Th cells upon activation, whereas the ‘standard’
proteasome is up-regulated in Tregs only upon
activation.
INTRODUCTION
The recent years have shown that regulatory T-cells (Treg)
play an essential role in the negative regulation of immune
answers and the prevention of autoimmunity (1) by main-
taining tolerance to self and controlling autoimmune de-
viation. Treg cells have an attenuated cytokine response
and can suppress proliferation and effector function of
other T-cells. One important regulator to develop the
Treg speciﬁc gene expression signature is the forkhead
box transcription factor FoxP3, which is highly expressed
in Treg cells, although it is also present at lower levels in
effector T-cell populations. Deﬁciency in FoxP3 has been
shown to underlie the lympho-proliferation and
multi-organ autoimmunity of mutant mice and is linked
with immunodysregulation polyendocrinopathy and the
X-linked syndrome (IPEX) in humans (2). Although
being a key regulator in Treg development, it becomes
also increasingly evident that FoxP3 alone only accounts
for part of the Treg signature and, for example, the sup-
pression of IL2 and activation of IL2RA in T-cells are also
found in FoxP3-deﬁcient Scurfy mice (3).
Treg cells differ signiﬁcantly in their gene expression
proﬁle from CD4
+ T helper cells, both, in resting and
activated states. A large number of gene expression
proﬁling studies (4–7) allowed for the identiﬁcation of a
signature of genes which are typically up- or
down-regulated in Tregs. Those genes are involved in a
variety of biologic processes and functions including cell
surface and membrane proteins (TLR4, IL2RA, IL2RB or
CTLA4), kinases (Map3K8), phosphatases (DUSP4) or
transcription factors (FoxP3, IKZF2 and IKZF4).
The role of FoxP3 in regulating the expression of Treg
speciﬁc genes has further been elucidated by three studies
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junction with microarrays to identify chromosomal loca-
tions of FoxP3 binding in mouse (8,9) and in human (10).
They described a set of  1400 mouse genes and 5579
human genes which are bound by FoxP3. In combination
with gene expression proﬁling, they identiﬁed genes which
are subsequently de-regulated in their expression levels.
Those studies showed that FoxP3 binding can explain ac-
tivation or repression of a subset of genes involved in the
Treg signature but also suggested that FoxP3 alone is not
responsible for developing Treg cells.
In addition, major advances in sequencing technologies
also known as next or second generation sequencing
(NGS) (11) allow for applications which go far beyond
what has been possible only a few years ago. Those appli-
cations include genome re-sequencing projects to identify
genetic variation between parents and their children (12)
or the analysis of folding principles of the human genome
(13). To gain a deeper understanding of properties of
a speciﬁc transcription factor, the combination of co-
immunoprecipitation and subsequent DNA sequencing,
also known as ChiP-seq (14,15), enables the unbiased
identiﬁcation of genomic regions bound by a transcription
factor. NGS has also enabled us to perform gene expres-
sion proﬁling (mRNA-seq) at an unknown depth, sensi-
tivity and resolution including the identiﬁcation of splice
variants (16), expression proﬁles of single cells (17) or or-
ganisms without prior genome sequence information (18).
In this study, we use Illumina’s Genome Analyzer
platform to perform ChiP-seq of FoxP3-bound genomic
regions and mRNA-seq for transcriptome proﬁling in
samples of resting and activated primary CD4
+ Th and
Treg cells from human donors. Using this data set, we are
able to show the inﬂuence of FoxP3 on gene expression
patterns in human and also in comparison to published
data sets in the mouse. Furthermore, our analysis enables
very detailed insights into the transcriptomal landscape of
resting and activated Treg and Teff cells including differ-
ential expression of genes, splice variants and ncRNAs.
MATERIALS AND METHODS
Preparation of T-cell populations
Leukapheresis products were obtained from adult healthy
volunteers with approval by the ethical committee
(Landesaerztekammer Baden-Wuertemberg). Human nat-
urally occurring CD4
+CD25
+ regulatory T-cells (Tregs)
and untouched human CD4
+ T helper cells (CD4
+ Th)
were isolated as described previously (19). Polyclonal
T-cell activation was performed using soluble 1mg/ml anti
CD3 (clone OKT3) antibody (ebioscience) and 2mg/ml anti
CD28 (clone 28.2) antibody (ebioscience).
FoxP3 ChiP
Genpathway’s FactorPath method was carried out as
described by Labhart et al. (20). In brief, human T-cell
populations, activated for 16h, were ﬁxed with 1% for-
maldehyde for 15min and quenched with 0.125M glycine.
Chromatin was isolated by adding lysis buffer, followed
by disruption with a Dounce homogenizer (cells). Lysates
were sonicated (Misonix) to shear the DNA to an average
length of 300–500bp. Genomic DNA (Input) was puriﬁed
from an aliquot of chromatin and quantiﬁed on a
Nanodrop spectrophotometer. Extrapolation to the
original chromatin volume allowed quantitation of the
total chromatin yield.
ChiP assays of activated Th cells and nTregs were
carried out in duplicate. An aliquot of chromatin (50ug)
was pre-cleared with protein G agarose beads
(Invitrogen). FoxP3-bound genomic DNA regions were
isolated using a goat polyclonal antibody against FoxP3
(Abcam ab2481). After incubation at 4 C overnight, pro-
tein G agarose beads were used to isolate the immune
complexes. Complexes were washed, eluted from the
beads with SDS buffer and subjected to RNase and pro-
teinase K treatment. Crosslinks were reversed by incuba-
tion overnight at 65 C and ChiP DNA was puriﬁed by
phenol-chloroform extraction and ethanol precipitation.
To assay for the enrichment of positive control region in
the ChiP DNA, quantitative PCR (qPCR) reactions were
carried out in triplicate with primers speciﬁc for these
regions using SYBR Green Supermix (Bio-Rad). The re-
sulting signals were normalized for primer efﬁciency by
carrying out qPCR for each primer pair using Input
DNA (data not shown).
ChiP Sequencing (ChiP-seq)
Remaining ChiP DNA (90% of entire sample) was ampli-
ﬁed using the Illumina ChiP-seq DNA Sample Prep Kit.
In brief, DNA ends were polished and 50-phosphorylated
using T4 DNA polymerase, Klenow polymerase and T4
polynucleotide kinase. After addition of 30-A to the ends
using Klenow fragments (30–50 exo
 ), Illumina genomic
adapters were ligated and the sample was size-fractionated
( 175–225bp) on a 2% agarose gel. After a ﬁnal PCR
ampliﬁcation step (18 cycles, Phusion polymerase), the re-
sulting DNA libraries were quantiﬁed and tested by qPCR
at the same speciﬁc genomic regions as the original ChiP
DNA to assess quality of the ampliﬁcation reactions.
DNA libraries were sent to Illumina Sequencing Services
for sequencing on a Genome Analyzer II resulting in  14
million quality-ﬁltered sequences of length 35 per sample.
mRNA Sequencing
Total RNA from CD4
+ Th and Treg cells was send to
Fasteris SA, Switzerland for sample preparation and
Illumina GA sequencing. Poly-A was puriﬁed with oligo-
dT magnetic beads (Dynabeads) and full length cDNA
was prepared using Superscript III reverse transcriptase
and RNAseH. The cDNA was fragmented by nebuliza-
tion and then treated as described above for the ChiP-seq
samples. After PCR ampliﬁcation the library was quality
controlled by cloning 1ml into a TOPO plasmid and eight
clones per library were Sanger sequenced. Libraries were
quantiﬁed using Q-bit picogreen assay (Invitrogen) and
BioAnalyzer (Agilent). Sequencing was performed on the
Genome Analyzer II for 2 36 cycles (paired-ends) using
sequencing kits version 2.0, 100 tiles per lane and data
analysis pipeline GAPipeline-1.0rc4.
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Short read data from mRNA-seq and ChiP-seq experi-
ments were mapped to the human genome (Ensembl 54)
using the Genomatix Mapping Station (21) allowing up to
4 mismatches and no gaps. Furthermore, mRNA-seq
reads were mapped to a database of artiﬁcial splice junc-
tions consisting of all pairs of exons in the human
Ensembl 54 release. Mapping to splice junctions was per-
formed using Bowtie (22) allowing for a maximum of two
mismatches on either side of the junction and requiring at
least 10 bases to match to one part of the junction.
Expression levels for genes were obtained by summariz-
ing all reads mapping to a gene in a sample and computing
the RPKM value for a gene as proposed by Mortazavi
et al. (23). RPKM values account for the different lengths
of genes as well as for the different number of reads mea-
sured in two experiments. Reads mapping multiple times
in the genome were assigned to the respective genes pro-
portional to the expression level of a gene as measured by
unique reads. Fold changes were computed as the ratio
of the RPKM values for measured for a gene in two
samples and the signiﬁcance of differential gene expres-
sion was computed using the SAGEBetaBin method
(24). Only genes with an absolute fold change >1.4 and
a SAGEBetaBin signiﬁcance score <0.01 were used for
further steps. For the analysis of de-regulated genes
measured by mRNA-seq, only genes with a minimal
RPKM value of eight in at least one of the four conditions
have been used.
Signiﬁcant clusters of FoxP3 bound sequences in ChiP-
seq data were identiﬁed using MACS (14) and a window
size of 300 bases, requiring for a P<10e
 6. The minimal
number of tags required for a cluster was determined from
the input data. Signiﬁcance values for the overlap between
set of genes identiﬁed to be bound by FoxP3 in different
species, i.e. mouse and human, were computed by the
hypergeometric test.
Results were interpreted in the context of biologic pro-
cesses and functions, as well as networks and pathways
through the use of Ingenuity Pathway Analysis (Ingenuity
Systems Inc., Redwood City, CA, USA).
RESULTS
In the following, we will discuss the results of the expres-
sion proﬁling (mRNA-seq) and the analysis of FoxP3
binding-sites by chromatin-immunoprecipitation (ChiP-
seq) experiments separately. The experimental setup is
shown in Figure 1. Finally, the integration of both data
sets allowed us to describe a more comprehensive under-
standing of the regulatory effects of FoxP3-binding in
human activated Treg and CD4
+ Th cells.
Expression proﬁling of human Treg and CD4
+ Th cells by
mRNA-seq
To analyze the transcriptomal landscape of primary
human CD4
+ Th and Treg cells, we sequenced the tran-
scriptome of resting and activated Treg and CD4
+Th cells
using Illumina’s mRNA-seq method. Basic read mapping
statistics are shown in Table 1. Expression proﬁling using
short read data was performed as described in the
‘Materials and Methods’ section and an overview on the
number of genes regulated in the different comparisons
can be found in Table 2. Genes with a signiﬁcant expres-
sion level (RPKM>8) in at least one population and a
log2 ratio (LR) of larger than one were taken into
account. The differences between two populations in a
state-speciﬁc manner have been compared, i.e. resting
Treg versus resting CD4
+ Th cells as well as activated
Figure 1. Schematic overview of the experimental setup and the differ-
ent human T cell populations used for RNA-seq and FoxP3 ChIP-seq
analysis.
Table 1. Read mapping statistics for mRNA-seq
Sample All reads Mapped
reads
Exonic
reads
Splice
junction
reads
Resting CD4
+ Th 15277248 13055740 9998139 551483
Activated CD4
+ Th 10335712 8397379 6473155 334714
Resting Treg 13655820 11567471 8817608 474661
Activated Treg 8237652 6650525 5407197 281711
The table is showing the total number of single reads (paired end reads
have been treated as two single reads), the number of reads mapping to
the human genome, the number of exonic reads as well as the number
of reads mapping to splice junctions.
Table 2. Differentially expressed genes (DEGs) by comparing the
RPKM values of separated T-cell populations
Comparison LR>1.0 LR< 1.0 LR>|1.0|
Treg act./Treg rest. 1056 1059 2115
CD4
+ Th act./CD4
+ Th rest. 924 926 1850
Treg rest./CD4
+ Th rest. 171 64 235
Treg act./CD4
+ Th act. 377 408 785
Shown are the numbers of genes which are either up-regulated
(LR>1.0) or down-regulated (LR< 1.0). The column LR>|1.0|
shows the overall differentially expressed genes, LR=log2 ratio.
7948 Nucleic Acids Research, 2011,Vol.39, No. 18Treg versus activated CD4
+ Th cells. Finally, the transi-
tion from resting to the activated phenotype within a
single cell type has been addressed. To qualify the conﬁ-
dence of the RNA-seq data, we proved the expression
pattern of known T-cell markers, which have been
described earlier as Treg-speciﬁc [e.g. FoxP3 (25,26),
HPGD (27), CTLA4 (28), ZNFN1A2 (29,30)], as CD4
+
Th cell speciﬁc [NKG7 (30), GZMB (30), CD40LG (31)]
or as activation-speciﬁc [BIC (6), IRF4 (32), TNFRSF9
(30)]: all of them conﬁrmed the expected expression
pattern (data not shown). In addition, we compared the
expression pattern of all 2115 genes (detected by RNA-seq
to be regulated by comparing activated Tregs versus rest-
ing Treg cells) to the recently published mRNA expression
proﬁling using Affymetrix Exon Arrays (E-TABM-779)
(6). As the protocols for the puriﬁcation of T-cell popula-
tions, the stimulation and the RNA extraction has been
exactly the same, the differences between these two studies
allowed us to address the differences based on the applied
technologies. As shown Figure 2A, only 406 (19%)
genes have been identiﬁed to be de-regulated by both
technologies (cut-off LR>|1.0|, e.g. FoxP3, Figure 2F).
Figure 2. Technology comparison of differentially expressed genes (Treg act. versus CD4
+Th cells). (A) Venn diagram for 2115 genes identiﬁed to be
regulated by RNA-seq. Only 406 genes (19%) have been identiﬁed by the Affymetrix Exon Array technology, i.e. FoxP3 (F). (B) Analysis of reasons
for not being detected by array technology. Of genes, 29% showed no regulation, i.e. PLEKHF1 (C); for 2% of genes no signiﬁcant expression was
detectable, i.e. HDC (D); only 42 genes showed a vice versa regulation pattern, i.e. RELB (E); 22% of genes the regulation could be conﬁrmed by
using a lower cuf-off for de-regulation (LR<|0.5|), i.e. PBX4 (G) and for 29% of genes no probeset was annotated at the Core data set using the
Affymetrix Exon Arrays. The bar chart diagrams show in red for RNA-seq (in log2 RPKM values) and in green for Affymetrix Exon arrays (in log2
values of RMA normalized expression) the relative expression pattern for all proﬁled T cell populations. RPKM=reads per kilobase of exon per
million mapped sequence reads, LR=Log2 ratio.
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regulated only by mRNA-seq and categorized the reasons
for their absence (Figure 2B). 613 genes (29%) showed a
signiﬁcant expression level, but no regulation using the
Affymetrix Exon Array technology (i.e. PLEKHF1,
Figure 2C). 42 genes (2%) have not shown any signiﬁcant
expression levels using the Affymetrix Exon Arrays (i.e.
HDC, Figure 2D). For only 8 genes a vice versa regulation
has been observed (i.e. RELB, Figure 2E). 592 genes
(28%) have not been measured on the microarray by
probesets using the Affymetrix Exon Array core
probeset annotation. By using the lower cuf-off of
LR>|0.5|, additional 465 genes (22%) have been
identiﬁed to be regulated also on the Exon Array
platform (i.e. PBX4, Figure 2G).
As recently described by Song et al. (33), also RNA-seq
might miss transcripts at lower expression levels. Low ex-
pression and potentially insufﬁcient transcript sampling
combined with high RPKM threshold result in differences
of differentially expressed genes, when compared to micro-
array experiments [645 genes are detected by arrays only
(Figure 2A)]. The ‘Materials and Methods’ section states
our very stringent threshold, that genes only with a
RPKM>8 in any of the four conditions have been incl-
uded. To overcome the sensitivity issue in future experi-
ments, a signiﬁcant higher number of mapped reads will
allow a decrease of the RPKM threshold. In summary, the
gain of information achieved by applying RNA-seq
weights out the loss of information by 2-fold in compari-
son to the Affymetrix Exon arrays.
Reasons for the discrepancies in results are mainly tech-
nology associated. The differences between microarrays
and RNA-seq protocols in IVT ampliﬁcation versus
PCR ampliﬁcation, in analogous versus digital signal de-
tection, in knowledge of sequences versus unbiased
sequencing, in regard to cross-hybridization versus distin-
guishing paralogous sequences, in spiked quantiﬁcation
versus absolute quantiﬁcation of low-abundance tran-
scripts have to be considered (17,34). In addition, the
RNA-seq offers the identiﬁcation of novel splice isoforms
and the detection of SNPs. Still, for many applications,
microarrays are the method of choice. Although the
pricing for RNA-seq is reaching comparable levels,
RNA-seq protocols still suffer from unknown biases
such as those implied by the required ligation steps, and
known biases where high abundance transcripts (house-
keeping genes and/or ribosomal transcripts) make up the
majority of sequencing data if not depleted (e.g. in some
tissues 5% of the genes represent up to 75% of the reads
sequenced).
Next we compared the global gene expression pattern
between activated Tregs and activated CD4
+ Th cells.
Therefore, we did not directly compare the gene expres-
sion levels of activated Tregs versus activated CD4
+ Th
cells. Instead of, we started to identify the genes which are
regulated upon activation within the Treg populations
(2115 genes) and CD4
+ Th cell populations (1850 genes)
independently. By comparing these two genesets, we were
able to identify a geneset of 1036 genes, which are specif-
ically regulated only in Treg cells (i.e. MS4A3, IL10,
GARP (LRRC32), TNIP3 or IL-13; Figure 3A) and a
geneset of 771 genes, which describe the genes speciﬁcally
regulated in CD4
+ Th cell activation (i.e. TNFSF13b,
DDT, FOS, CXCL11 or NR4A2, Figure 3C). Finally, a
common geneset of 1079 genes was deﬁned, which
contains genes regulated in Tregs as well as in CD4
+ Th
cells upon 16h activation (i.e. SCD, IL22, FoxP3 or
TSPAN2, Figure 3B). The three activation-speciﬁc
genesets are shown as Venn diagram in Figure 3D and
listed as Supplementary Table S1.
The novel ﬁnding for Il-13 was proven by RT-PCR (not
shown). Upon analyzing the RNA-seq data for additional
CD4
+ Th/CD4 memory cell marker gene expression
(IFNg, IL4, CCR7, as well as CD62L), we are pretty con-
ﬁdent that the IL-13 expression pattern did not originate
from cell impurities, as it is expressed at that high levels in
activated TREGs and did not show a major expression in
activated Th cells.
Subsequently, Ingenuity Pathway Analysis was used to
analyze the activation-speciﬁc genesets to enrich inﬂu-
enced signaling pathways. We found 62 canonical signal-
ing pathways scored with a signiﬁcant  log10[P-value]>2
(Fisher’s exact test) for at least one of the three genesets
(Figure 3E). Upon activation, CD4
+Th cells signiﬁcantly
modulate IRF signaling, MAPK signaling, Tweak signal-
ing, Il-6 signaling, NFkB activation, CD40 signaling,
CD27 signaling and TNFR1 as well as TNFR2 signaling,
whereas none of these canonical pathway were affected
by activation of Tregs (Figure 3E). The other way
around, Treg cells signiﬁcantly modulate upon activation:
Glucocorticoide receptor signaling, VEGF signaling,
PI3K/AKT signaling, T-cell differentiation, PKCtheta sig-
naling, NRF2 signaling, T-cell receptor signaling, ICOS
signaling as well as the Protein Ubiquitination pathway
(Figure 3E).
Each modulated signaling pathway was overlaid by the
expression data to visualize the biologic signiﬁcance, i.e.
the Protein Ubiquitination Pathway with the LR (log2
expression changes) of Treg cells as well as with the LR
of CD4
+Th cells as shown in Figure 3F or G. In CD4
+Th
cells the proteasome is not affected by the activation
thereof (Figure 3G). But speciﬁcally in activated Tregs a
couple of the proteasome subunits are found to be strongly
up-regulated (Figure 3F). The proteasome is a large
multicatalytic complex which drives organized protein
degradation. The proteasome plays a straightforward
but critical role in the function of the adaptive immune
system. Peptide antigens are displayed by the major histo-
compatibility complex class I (MHC) proteins on the sur-
face of antigen-presenting cells. These peptides are
products of proteasomal degradation of proteins ori-
ginated by the invading pathogen. Although constitutively
expressed proteasomes can participate in this process, a
specialized complex composed of proteins whose expres-
sion is induced by interferon gamma produces peptides of
the optimal size and composition for MHC binding. These
proteins whose expression increases during the immune
response include the 11S regulatory particle, whose main
known biologic role is regulating the production of MHC
ligands, and specialized b subunits called b1i, b2i and b5i
with altered substrate speciﬁcity. The complex formed
with the specialized b subunits is known as the
7950 Nucleic Acids Research, 2011,Vol.39, No. 18Figure 3. Pathway Analysis of T cell activation. Shown are (A) genes speciﬁcally regulated upon activation of Treg cells. (B) Genes commonly
regulated upon activation in both cell populations and (C) genes speciﬁcally regulated upon activation of CD4
+ Th cells. (D) The Venn diagram
shows the intersection of the activation signatures of CD4
+Th and Treg cells. (E) The three activation-speciﬁc genesets shown in Venn diagram have
been used in Ingenuity Pathway Analysis to enrich inﬂuenced signaling pathways. Sixty two canonical signaling pathways scored with a signiﬁcant
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(continued)immunoproteasome (35). The immunoproteasome seems
to be up-regulated in both Treg and CD4
+ Th cells upon
activation, whereas the ‘standard’ proteasome is only
up-regulated in Tregs upon activation (Figure 3F or G).
This Treg speciﬁc regulation might explain the observa-
tion that long term culture of CD4
+ Th cells in the
presence of a small molecule inhibitor for LMP7 (also
known as PSMB8, a catalytic subunit of the
immunoproteasome) gave rise to a increased regulatory
T-cell population (36).
Figure 4 displays the some interesting marker genes dis-
tinguishing Treg from CD4
+ Th cells. The complete
picture can be found in Supplementary Table S1. Those
include general Treg marker genes like FoxP3, CTLA4,
TLR4, IL2RA and IL2RB as well as Treg speciﬁc activa-
tion markers [e.g. CABLES1, GARP (LRRC32) and
TNFRSF18 (GITR)] that are found to be speciﬁcally
up-regulated in activated Tregs only. Some of those
genes correspond to newly identiﬁed lineage markers
(i.e. HDC, BTK and GATA2) which have not been
described before.
Finally, as shown in Figure 2F, FoxP3 is found to be
expressed in all four samples. Low expression levels are
found in CD4
+ Th cells (resting expression level: 1.9
RPKM, activated expression level: 4.6 RPKM). In
contrast, expression in Treg cells is >10-fold higher with
an RPKM value of 27.4 in resting and 48.8 in activated
Treg cells. Genes, whose promoters are bound by FoxP3
and the implications of FoxP3 binding on gene expression
are discussed in detail below.
Identiﬁcation of splice variant expression in
mRNA-seq data
Alternative splicing plays important roles in many
biologic processes (37) and has also been described to be
of importance in the immune system (38) and also during
T-cell activation (39). In addition to the detection in gene
expression levels, the mRNA-seq technique allows also the
analysis for splice variants. Dependent of the complexity
of gene-speciﬁc splicing behavior, present or absent tran-
scripts are detectable for each sample.
For IRAK1 (Interleukin receptor 1 associated kinase), a
serine/threonine kinase, three different splice variants with
opposing function are known (38,40). In our data set we
ﬁnd two splice variants (full length IRAK1 and IRAK1c)
to be expressed. The full-length isoform of IRAK1 is de-
tectable only in resting cell states of Tregs and CD4
+ Th
cells. Upon activation of these cells, exon 11 seems to be
skipped: surprisingly, only the truncated isoform IRAK1c
is detectable in activated CD4
+ Th cells (Figure 5A). The
skipped exon encodes to the C-terminal part of the kinase
domain. This smaller variant isoform therefore likely lacks
kinase activity, although it retains the ability to interact
with many IRAK1-binding partners. It may function as a
negative-feedback loop in which IRAK1 function is
decreased in response to IL-1 stimulation. The presence
and regulation of the truncated form of IRAK1 was
proven indirectly by qRT–PCR using Roche’s UPL tech-
nology (Supplementary Figure S1).
SAM68 (shown in Figure 5B) is a protein which is re-
cruited to the T-cell receptor and, once phosphorylated,
functions as an adapter protein in signal transduction
cascades by binding to SH2 and SH3 domain-containing
proteins. In our data set, splicing events skipping the KH
domain (PF00013), a domain known to be important for
RNA binding, occurs only in resting CD4
+ Th and Treg
cells but is not observed in activated states. Variants
lacking the KH domain have been shown to be expressed
in growth-arrested cells only and are known to inhibit S
phase (41).
For AUF1 (Heterogeneous nuclear ribonucleoprotein
D0), shown in Figure 5C, different rates for the inclusion
and exclusion of a Glycin-rich region are found. This
region was shown to be important for the RNA-binding
function (42). While in resting CD4
+ Th and Treg cells
both isoforms (with and/or without exon7) seem to be
expressed at equal levels, a clear shift towards the
isoform skipping exon7 is detectable in activated Treg
cells. Evidence is shown in Figure 5 by the expression
level of exon 7 and the number of junction reads voting
for either variant (data not shown). The presence,
majority and the regulation of the truncated form of
AUF1 was conﬁrmed by qRT–PCR using Roche’s UPL
technology (Supplementary Figure S2).
Two different splice variants have been described for
FoxP3 in human (43). One isoform originates from an
in-frame exon skipping event of exon 3 (protein coding
exon 2) leading to a protein product which lacks 34
amino acids. Neither the forkhead nor the zinc-ﬁnger
domains are affected by this event. Both variants have
also been shown to be functional (43) such that their
biologic role still has to be elucidated. In our mRNA-
seq data, both variants are detected as being present in
resting Treg cells. In activated Treg cells the number of
reads mapping the 50-end of the gene is very small and,
likely due to missing data, no indication for the skipping
event is found.
Other proteins for which differentially expressed splice
variants are detected are IL2RA, LEF1 (both express
mixtures of transcripts) and FYN. Speciﬁcally between
resting and activated cell states for FYN different inclu-
sion rates are found. Overall, this data displays the poten-
tial of mRNA-seq data to enable the analysis of state and
cell speciﬁc splice variant expression and highlights the
fact that interesting and important functions during
CD4
+ Th and Treg activation may be mediated and per-
formed through differentially expressed isoforms.
Figure 3. Continued
 log10[P-value]>2 for at least one of the three genesets. (F) The overlay of the epression data as LRs to the Protein Ubiquitination Pathway
identiﬁed a couple members of the protease to be speciﬁcally up-regulated in activated Tregs, whereas no modulation of these has been observed after
activation of CD4
+ Th cells (G). The bar chart diagrams show the relative expression pattern for all in RNA-seq experiments proﬁled T cell
populations in log2 RPKM values. RPKM=reads per kilobase of exon per million mapped sequence reads, LR=Log2 ratio.
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populations and comparison to array-based
measurements in mouse and human
We performed ChiP-seq to identify genomic regions which
are bound by FoxP3 in activated CD4
+ Th and activated
Treg cells of two human donors (biologic replicates).
FoxP3-bound genomic DNA fragments from CD4
+ Th
and Treg cells were sequenced as described in the
‘Material and Methods’ section. Short sequence reads
were mapped to the human genome and signiﬁcant
peaks, i.e. clusters of reads, were identiﬁed using MACS
(14) and the cluster statistics are displayed in Table 3. In
both cell populations and biologic replicates a large
number of clusters were found, with many more clusters
in Treg cells compared to CD4
+ Th cells, likely due to
higher expression levels of FoxP3. Clusters are mapped
to intergenic, intronic, exonic or known promoter
regions and, as shown in Figure 6, promoter regions
appear to be highly enriched. They are mapped 14 to 24
times more often than expected by chance. As shown in
Table 3, 32–51% of all clusters are mapped to known
promoter sites (Ensembl 54). Genes detected in different
biologic replicates overlap to a large extent. With respect
to the smaller data set, 1264 (80.7%) of the CD4
+Th cell
genes and 5627 (88.7%) of the Treg genes are identiﬁed in
both biologic replicates indicating that the experiment in
general returns highly reproducible results. 1170 genes
(74% of the genes identiﬁed in sample A1) are detected
in all four samples to be bound by FoxP3. Further, 1317
genes are found in A2 as well as B1 and B2. Those 2487
genes are likely to represent a set of genes which is bound
by FoxP3 in both cell types. Only 26 genes are found in
CD4
+ Th cells only (samples A1 and A2). In contrast,
2897 genes are identiﬁed whose promoters are only
bound by FoxP3 in Treg cells and which are candidates
for a Treg speciﬁc regulatory effect of FoxP3.
To further evaluate the quality of the FoxP3 clusters ob-
tained in our experiment we tested to what extent ChiP-
seq clusters are associated to DNAse I hypersensitive sites
from human primary CD4
+T-cells which have been pub-
lished by Boyle et al. (44). DNAse I hypersensitive sites
have been historically used to identify the location of regu-
latory regions, including enhancers, silencers, promoters
and other locus control regions and can therefore provide
additional evidence regarding data quality. The DNAse I
sites were mapped onto the human genome and were sub-
sequently clustered by MACS. As shown in Figure 6,
DNAse I hypersensitive sites found in all four genomic
categories but, just like FoxP3 clusters, they are highly
enriched in promoter regions. The overlap between
Figure 4. Set of genes and their subcellular localization which are up-regulated in Treg cells compared to CD4
+ Th cells. Genes shown in green are
up-regulated in activated and resting Treg cells; orange genes are up-regulated upon activation of Treg cells but are not up-regulated upon CD4
+Th
activation. The red stars mark genes which are bound by FoxP3 in activated Treg cells.
Nucleic Acids Research, 2011,Vol.39, No. 18 7953FoxP3 clusters and DNAse I clusters is even higher than
the overlap of FoxP3 clusters with promoter regions.
Between 55 and 68% of all FoxP3 clusters overlap with
DNAse I clusters. Therefore, a larger fraction of FoxP3
binding sites which do not map to known promoter sites
might be bound in other regions of regulatory relevance
(i.e. cis- and/or trans-active regulatory elements like enhancer
or silencers).
Using the Genomatix collection of transcription factor
binding matrices, we searched for other, enriched
Figure 5. Examples for the detection of splice variants in Treg and CD4
+ Th cells. Exons of the genes are shown in blue, read coverage at a speciﬁc
position is indicated by the orange bars. Examples for known transcript models of a gene are shown below the gene structures where solid lines
indicate that a speciﬁc splice junction has been identiﬁed in the data while dotted lines indicate that a junction has not been found. Green bars
indicate the location of speciﬁc protein domains. (A) displays changes in the expression of exon 11 between resting and activated CD4
+ Th cells
corresponding to the partial deletion of the kinase domain (shown by the green bar) of IRAK1.( B) For the SAM68 gene, exon skipping of exon 3
which represents a KH RNA binding domain (PF00013, indicated by the green bar) is only observed in resting Treg and CD4
+Th cells and never in
activated states. (C) For AUF1 inclusion or exclusion of a Glycin-rich region (shown by the green bar) is found to occur in different levels in
activated Treg and CD4
+ Th cells compared to resting states.
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bound by FoxP3. In both biologic replicates (B1 and B2)
several transcription factor binding matrices are identiﬁed
in FoxP3 bound regions more often than expected.
Among the top scoring matrix families, four appear to
be especially interesting in the biologic context. This
includes the ETS-1 as well as the HAML (human acute
myelogenous leukemia) factor family. Cooperative
binding of members of the two families has been described
in several cases in the context of T-cells including the co-
operative binding of AML1 and Ets-1 to the TCR alpha
enhancer (45) as well as composite binding of Ets-1 and
CBF (another member of the HAML family) in the regu-
lation of antigen receptor genes (46). Futhermore, binding
sites for AP1F are overrepresented in FoxP3 bound
regions. Members of this family are known to interact
with both HAML and ETSF in various cases including
the activation of GM-CSF in T-cells (47) and FoxP3 has
been shown to suppress AP-1 transcriptional activity (48).
Finally, interferon regulatory factor (IRFF) binding sites
are overrepresented. A member of this family, IRF4, has
been described to interact with multiple Ets factors to
modulate CD68 expression in a cell type-speciﬁc manner
(49). Also, it has only recently been shown (50) that in
mouse Treg cells, high amounts of interferon regulatory
factor-4 (IRF4) is dependent on Foxp3 expression. The
authors proposed that IRF4 expression endows Treg
cells with the ability to suppress TH2 responses a fact
which might be conﬁrmed by the over-representation of
IRFF binding sites in FoxP3 bound genes such that col-
laborative binding might occur. The NFAT transcription
factor motif which has been shown previously to interact
with FoxP3 (51) is also overrepresented although less sig-
niﬁcantly than the four matrices described above.
Next, we tested to what extent genes bound by FoxP3 in
our human data set have also been identiﬁed in two
studies by Zheng et al. (8) and Marson et al. (9) that ana-
lyzed FoxP3 occupancy in mouse and one recent study by
Sadlon et al. (10) who identiﬁed human FoxP3 targets
using ChiP-on-Chip experiments. In the Zheng data set,
1277 FoxP3 binding sites are annotated which correspond
to 519 mouse genes in Ensembl 54. Out of those 454 can
be mapped to a corresponding human ortholog and are
used in subsequent analysis steps. In the Marson data set,
1335 binding sites in unstimulated and 1119 binding sites
in stimulated hybridoma cells were identiﬁed (at a false
discovery rate of 5%) which map to 1265 and 1055
distinct mouse genes. Out of those 1162 genes in unstimu-
lated and 960 genes in stimulated cells have an annotated
ortholog in the human genome. The 5579 genes identiﬁed
by Sadlon et al. (10) in human correspond to 4185 human
genes in Ensembl 54. The overlap between the genes in the
three published data sets and the 5627 human FoxP3
bound genes in Treg cells is shown in Figure 7. It is inter-
esting to note that the overlap of the two published mouse
data sets is relatively small. Only 107 genes are detected in
both data sets. Although this overlap is highly signiﬁcant
(P<1.66e
 42) it shows that even within the same species
larger differences in genes detected to be bound by FoxP3
can be expected either due to the experimental design like
cell lines or stimulation or due to genetic and biologic
variance. Human FoxP3 bound genes in our data set sig-
niﬁcantly overlap with mouse genes. The human data set
contains 181 genes detected in the Zheng study
(P<1.91e
 14) and 561 genes from the Marson data set
(P<3.453e
 77). 58 genes are found in all three studies and
743 genes are found in at least two data sets (49 of which
are only found in the mouse). The largest and most sig-
niﬁcant overlap is found for the two human data sets.
1586 genes are consistently identiﬁed in both data sets as
FoxP3 target genes (P<1.65e
 112) and are therefore con-
sistent between two different experimental setups and two
different technologies.
The effects of FoxP3 binding onto gene expression in
human T-cells
As described above, 2897 genes are speciﬁcally bound by
FoxP3 in activated Treg cells, 26 only in CD4
+ Th cells
and 2487 genes are bound in both cell types. We integrated
Table 3. FoxP3 cluster statistics for CD4
+ Th and Treg cell populations obtained by Illumina ChiP-seq in two biologic
replicates
CD4
+ Th (A1) CD4
+ Th (A2) Treg (B1) Treg (B2)
Total number of clusters 4429 7524 25341 22558
Clusters overlapping with promoters 1873 3876 8202 8976
Clusters overlapping with DNAse I sites 2930 5153 13956 14207
Distinct genes mapped in promoter regions 1566 3345 6341 7584
Genes mapped in both biologic replicates 1264 5627
Figure 6. Cluster statistics for human FoxP3 clusters identiﬁed by
MACS which shows the high enrichment of promoter elements
overlapping with MACS clusters. Biologic replicates of isolated
human CD4
+ T-cells (A1 and A2) and human regulatory T-cells
(B1 and B2).
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seq experiment of activated CD4
+ Th and activated Treg
cells, as discussed above. 3255 genes have been identiﬁed
to be signiﬁcantly regulated (absolute fold-change >1.4
and signiﬁcance value <0.01) between activated CD4
+
Th and Treg cells by mRNA-seq analysis. 1451 (44%) of
those genes are also bound by FoxP3 either in Treg only
(800 genes, 399 up-regulated, 401 down-regulated) or in
Treg and CD4
+Th cells (647 genes, 362 upregulated, 285
downregulated). The fact that 44% of all regulated genes
between activated Treg and CD4
+ Th cells are bound by
FoxP3 proofs its important role for activated Treg cells.
The overlap is statistically highly signiﬁcant
(P<4.55e
 193). Marson et al. (9) described a highly sup-
pressive function of FoxP3 in their data set where many
more genes were down-regulated than up-regulated upon
FoxP3 binding, a view which has also been taken by
Ziegler et al. (2). In contrast to those ﬁndings and in cor-
respondence with the Zheng study (8), our human data set
suggests that activation and repression of genes by FoxP3
seem to be well balanced.
The gene which shows the highest up-regulation
(17-fold) in Treg cells is CTLA4 which is bound by
FoxP3 according to ChiP-seq data in two clusters as
shown in Figure 8A. Other examples are IL1R1 (up-
regulation: 13-fold), DUSP2, DUSP4 and DUSP6 (up to
8-fold) as well as CXCR6 and CCR4 (up to 4-fold).
Interestingly, FoxP3 binds to its own promoter in Treg
cells and may therefore regulate its own expression levels.
On the other hand, 401 genes bound by FoxP3 are sig-
niﬁcantly down-regulated in Treg cells. In our data set
those genes include DPEP2 (60-fold down-regulated),
ITGA4 (6-fold), TLR1 (7-fold), IFIT2 (8-fold), TRAT1
(3-fold) which is a positive regulator of the T-cell
receptor signaling pathway as well as members of the
TRIM (tripartite motif-containing) family (TRIM21,
TRIM22, TRIM38, TRIM56). TRIM21 is known to
increase IL2 production in T-cells (52).
2487 genes are bound by FoxP3 in activated CD4
+ Th
and Treg cells. Out of those, 647 (26%) genes appear to be
signiﬁcantly de-regulated in the comparison between the
two cell types. Although there is no general correlation
between binding strength (as measured by the number of
reads found in a promoter cluster) and the resulting fold
change in the gene expression measurement (see
Supplementary Table S2), for 503 of those 647 genes
(78%) binding strength is at least 2-fold higher in Treg
cells compared to CD4
+ Th cells. 362 genes are
up-regulated in Treg cells while 285 genes are
down-regulated. For example, IL16 and LY9 (lymphocyte
antigen 9), which are both shown in Figure 8B and C, as
well as IL7R appear to be down-regulated, while e.g.
RGS1, IL2RB, FOS and FOSL2 (both part of the AP-1
transcription complex) are up-regulated.
Interestingly, the up-regulation of proteasome compo-
nents in Treg cells discussed above clearly seems to be
mediated by FoxP3 as many proteasome genes are
bound by FoxP3 in their promoter regions (see also
Figure 7. Comparison of FoxP3 bound genes in human T-reg cells and three published data sets in mouse and human. FoxP3 target genes published
by other groups have been identiﬁed using array based technologies (ChIP on Chip).
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of IL16, FoxP3 may also be involved in the use of
speciﬁc alternative transcription start sites in order to
mediate expression of the T-cell speciﬁc isoform of the
gene.
DISCUSSION
Treg cells play an essential role in the negative regulation
of immune answers and FoxP3 has been shown to be one
of the major regulator genes for developing the Treg gene
signature. But despite many research in the ﬁeld the mech-
anisms leading to the speciﬁc gene expression patterns
are not completely understood. The last years have also
shown that transcription factor binding maydiffer strongly
from species to species such that results achieved in one
model organism may not necessarily be transferred to
others.
In this study we have analyzed for the effects of FoxP3
transcription factor binding on the development of the
Treg gene signature in humans using the most recent
and also most sensitive technological platforms available.
We combined two approaches relying on next generation
sequencing, namely mRNA-seq and ChiP-seq, which, in
combination, allow for very detailed insights into the
complex transcriptomal landscape of higher eukaryotes.
We have performed expression proﬁling of resting and
activated Treg and CD4
+Th cells and identiﬁed gene sig-
natures that are speciﬁcally de-regulated in the different
cell types (Treg and CD4
+ Th signature) or are regulated
in both cell types upon activation (Activation signature).
Signatures were compared to sets of genes identiﬁed in a
similar study using Affymetrix Exon Arrays. In corres-
pondence with other authors we ﬁnd that while the key
players are identiﬁed by both technologies, NGS can iden-
tify many more de-regulated genes likely to its higher sen-
sitivity and the fact that any gene can be proﬁlied without
Figure 8. Examples for the modulation of transcript expression by FoxP3. Exons of the genes are shown in blue, read coverage at a speciﬁc position
is indicated by the red (activated Treg cells) and blue (activated CD4
+ Th cells) lines. Examples for known transcript models of a gene are shown
below the gene structure. Green arrows indicate positions of signiﬁcant FoxP3 binding site peaks identiﬁed in activated Treg cells of both donors.
(A) shows the up-regulation of CTLA4 likely mediated by two FoxP3 clusters, (B) LY9 is bound by FoxP3 at multiple sites in both cell lines but
binding strength is 10  higher in Treg than in CD4
+TH cells, leading to the almost complete repression of the gene in Treg cells, (C) Short isoforms
of the IL16 gene are known to be speciﬁcally expressed in T-cells. Expression and repression of the short variant of the gene may be mediated by
FoxP3 which is bound to multiple sites of the gene including the promoter site of the short isoform in both cell types.
Nucleic Acids Research, 2011,Vol.39, No. 18 7957having to rely on pre-deﬁned sets of probesets. Analysis of
de-regulated pathways shows signiﬁcant differences be-
tween Treg and CD4
+ Th cells not only on the level of
single genes.
Furthermore, using NGS data we can identify differ-
ences in splicing patterns like the expression of a
kinase-dead isoform of the IRAK1 gene upon T-cell acti-
vation. Although it is not yet clear what function this
kinase-dead isoform has in vivo, it is interesting to note
that expression of the small isoform has been shown to be
speciﬁc for activated Treg and CD4
+ Th cells whereas
both cell types express the full length isoform in resting
states. Overexpression of IRAK1c in 293T or G292 cells
suppressed NF-kB activation and blocked IL-1b-induced
IL-6 as well as LPS and CpG-induced TNFa production.
Mechanistically evidence was shown that IRAK1c func-
tions as a dominant negative by failing to be phosphory-
lated by IRAK4, thus remaining associated with Tollip
and blocking NF-kB activation (40). The presence of a
regulated, alternative splice variant IRAK1c in activated
T cells, that functions as a kinase-dead, dominant-negative
protein adds further complexity to the variety of mechan-
isms that regulate TIR signaling and the subsequent in-
ﬂammatory response.
By using ChiP-seq we identiﬁed genes bound by FoxP3
in activated Treg and CD4
+ Th cells. By identifying
promoter regions with signiﬁcant FoxP3 peaks in short
read data we obtained a set of more than 5000 genes
which may be subject to a FoxP3 mediated regulation of
the corresponding gene. Genes identiﬁed to be bound in
human show a highly signiﬁcant overlap with two pub-
lished FoxP3 data sets in the mouse, although many more
genes were identiﬁed in human. This is likely due to the
higher sensitivity of ChiP-seq compared to array-based
detection methods which again require a priori know-
ledge. Promoter regions bound by FoxP3 additionally
show enrichment for other transcription factor binding
sites like ETS-1, HAML, AP1 and IRFF (including
IRF4) which are novel candidates for a cooperative
function in controling T-cell development in human.
Especially the correlation of FoxP3 binding sites with
IRF4 appears to be interesting, as IRF4 has only recently
been shown to be transcriptionally dependent on FoxP3.
In a last step, we combined both data sets in order to
understand the regulatory effects of FoxP3 on the speciﬁc
gene expression signature of Treg cells. More than 40% of
the genes which appear to be de-regulated in activated
Treg cells compared to activated CD4
+ Th cells are
bound by FoxP3 in their promoter regions showing the
large importance of this transcription factor for develop-
ing the Treg signature. In contrast to some previous
studies which proposed the major function of FoxP3 as
a suppressor, we ﬁnd that activation and repression of
genes by FoxP3 are likely to be well balanced in human.
Nobody before proﬁled that comprehensively human
primary T cell populations. The functional relevance of
the identiﬁed FoxP3-bound genes has been conﬁrmed by
earlier studies. In 2009, we published the functional rele-
vance of FoxP3-bound miR-155 in sensititation CD4
+Th
Cells for TREG mediated suppression (53). In addition,
we (in human) and others (in mouse) could identify
PDE3b as a FoxP3 target gene (54). PDE3b is involved
in controlling the abundance of cyclic adenosine mono-
phosphate (cAMP) and cAMP is known to suppress
T cell function. Because Foxp3 blocks PDE3B expression,
regulatory T cells may contain higher amounts of cAMP,
which may play an important role in regulatory T cell
function (54,55). Further examples for TREG-mediated
T cell suppression of FoxP3 target genes have been
described: DAB2 (56), CTLA4 (57) and EBI3 (IL-27/
IL-35) (58). Beyond these selected examples, we did inte-
grate the human FoxP3 occupancy and expression data
with expression proﬁles derived from T cell populations
of scurfy mice (FoxP3-deﬁcient) (59,60). We downloaded
the raw data (E-GEOD-11775), normalized, orthologous
aligned (mouse to human) and integrated them with
FoxP3-bound genes. A signiﬁcant overlap of FoxP3-
bound genes (ChIP-seq), which have been identiﬁed to
be regulated upon T cell activation in human (RNA-
seq), revealed no major regulation in activated T cell
populations from scurfy mice (data not shown).
Although there are differences in FoxP3 function and ex-
pression between human and mouse (61), by that kind of
analysis we have been able to show indirect proof of func-
tional relevance for the FoxP3-bound genes.
Taken together our study provides a comprehensive
data set which allows analyzing the FoxP3 dependent de-
velopment of the Treg gene signature as well as the differ-
ences between Treg cell and CD4
+Th cells in general. The
use of next generation sequencing provides signiﬁcantly
deeper insights into the complex transcriptomal landscape
of higher eukaryotes compared to array-based tech-
nologies and will help to further sharpen our understand-
ing of transcriptional regulation of gene expression by
transcription factors in the future.
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Supplementary Data are available at NAR Online. The
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